Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

[1]  T. Waldmann,et al.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. , 2013, Blood.

[2]  K. Nakai,et al.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. , 2012, Immunity.

[3]  V. Pande,et al.  Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15 , 2012, Nature Immunology.

[4]  H. Jäck,et al.  miR‐9 enhances IL‐2 production in activated human CD4+ T cells by repressing Blimp‐1 , 2012, European journal of immunology.

[5]  J. O’Shea,et al.  Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. , 2012, Current opinion in pharmacology.

[6]  J. Seavitt,et al.  Aiolos promotes TH17 differentiation by directly silencing Il2 expression , 2012, Nature Immunology.

[7]  M. Sigvardsson,et al.  Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. , 2012, Immunity.

[8]  M. Kaplan,et al.  The symphony of the ninth: the development and function of Th9 cells. , 2012, Current opinion in immunology.

[9]  T. Randall,et al.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. , 2012, Immunity.

[10]  S. Verstovsek,et al.  Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? , 2012, British journal of haematology.

[11]  T. Honjo,et al.  TRIM28 prevents autoinflammatory T cell development in vivo , 2012, Nature Immunology.

[12]  Kairong Cui,et al.  Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. , 2012, Immunity.

[13]  Steven A. Rosenberg,et al.  Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.

[14]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[15]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[16]  Jeffrey A. Diamond,et al.  STAT5 is a potent negative regulator of TFH cell differentiation , 2012, The Journal of experimental medicine.

[17]  K. Oestreich,et al.  Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile , 2012, Nature Immunology.

[18]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[19]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[20]  T. Malek,et al.  The Basis of Distinctive IL-2– and IL-15–Dependent Signaling: Weak CD122-Dependent Signaling Favors CD8+ T Central-Memory Cell Survival but Not T Effector-Memory Cell Development , 2011, The Journal of Immunology.

[21]  A. Laurence,et al.  Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. , 2011, Immunity.

[22]  Ramon Arens,et al.  Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cells , 2011, Nature Immunology.

[23]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[24]  W. Leonard,et al.  Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages , 2011, Nature Immunology.

[25]  J. Mcgregor,et al.  Endothelial Nitric Oxide Synthase Is a Key Mediator of Interleukin-2-Induced Hypotension and Vascular Leak Syndrome , 2011, Journal of immunotherapy.

[26]  T. Waldmann,et al.  A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy , 2011, Nature Medicine.

[27]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[28]  J. O’Shea,et al.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5 , 2011, Nature Immunology.

[29]  Eunjung Jang,et al.  Transcription factor T-bet represses TH17 differentiation by preventing Runx1-mediated activation of the RORγt gene , 2010, Nature Immunology.

[30]  Na Li,et al.  The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes , 2010, Nature Immunology.

[31]  Anjana Rao,et al.  NFAT, immunity and cancer: a transcription factor comes of age , 2010, Nature Reviews Immunology.

[32]  T. Malek,et al.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.

[33]  A. Jha,et al.  IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery , 2010, Journal of Clinical Immunology.

[34]  W. Paul,et al.  How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.

[35]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[36]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[37]  A. Rudensky,et al.  Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate , 2010, Nature.

[38]  W. Haining,et al.  Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.

[39]  M. Bevan,et al.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.

[40]  Dorothea Busse,et al.  Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments , 2010, Proceedings of the National Academy of Sciences.

[41]  Francesca Meloni,et al.  An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. , 2010, Blood.

[42]  Y. Belkaid,et al.  Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. , 2009, Immunity.

[43]  W. Leonard,et al.  New insights into the regulation of T cells by γc family cytokines , 2009, Nature Reviews Immunology.

[44]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[45]  M. Laughlin,et al.  microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4+ T cells. , 2009, Blood.

[46]  E. Shevach.  Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.

[47]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[48]  J. Schultze,et al.  CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. , 2008, Immunobiology.

[49]  Dustin E. Schones,et al.  Priming for T helper type 2 differentiation by interleukin 2-mediated induction of IL-4 receptor α chain expression , 2008, Nature Immunology.

[50]  K. Calame,et al.  Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival , 2008, The Journal of experimental medicine.

[51]  L. Berg,et al.  Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. , 2008, Immunity.

[52]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[53]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[54]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[55]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[56]  J. Gatell,et al.  Expression and function of the IL‐2 receptor in activated human plasmacytoid dendritic cells , 2007, European journal of immunology.

[57]  W. Leonard,et al.  CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation , 2007, The Journal of experimental medicine.

[58]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[59]  T. Waldmann.  Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma , 2007, Oncogene.

[60]  E. Shevach,et al.  Cutting Edge: IL-2 Is Essential for TGF-β-Mediated Induction of Foxp3+ T Regulatory Cells , 2007, The Journal of Immunology.

[61]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[62]  S. Zheng,et al.  IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.

[63]  Jean Imbert,et al.  Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. , 2006, Cytokine & growth factor reviews.

[64]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[65]  J. Stroud,et al.  FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT , 2006, Cell.

[66]  Linda V. Sinclair,et al.  Differential regulation of T-cell growth by IL-2 and IL-15. , 2006, Blood.

[67]  T. Šarić,et al.  CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. , 2006, Blood.

[68]  Fuping Zhang,et al.  T helper type 1–specific Brg1 recruitment and remodeling of nucleosomes positioned at the IFN-γ promoter are Stat4 dependent , 2006, The Journal of experimental medicine.

[69]  A. Tyznik,et al.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.

[70]  C. Klebanoff,et al.  Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo1 , 2006, The Journal of Immunology.

[71]  Sanjeev Galande,et al.  Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. , 2006, Molecular cell.

[72]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[73]  Ian A Wilson,et al.  Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Kastelein,et al.  IL-27 Limits IL-2 Production during Th1 Differentiation1 , 2006, The Journal of Immunology.

[75]  K. Garcia,et al.  Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.

[76]  W. Leonard,et al.  Smad-dependent Cooperative Regulation of Interleukin 2 Receptor α Chain Gene Expression by T Cell Receptor and Transforming Growth Factor-β* , 2005, Journal of Biological Chemistry.

[77]  J. Berzofsky,et al.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function , 2005, The Journal of experimental medicine.

[78]  E. Rothenberg,et al.  Preferential Activation of an IL-2 Regulatory Sequence Transgene in TCRγδ and NKT Cells: Subset-Specific Differences in IL-2 Regulation1 , 2004, The Journal of Immunology.

[79]  W. Paul,et al.  Interleukin 2 plays a central role in Th2 differentiation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[81]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[82]  John Kuriyan,et al.  A reinterpretation of the dimerization interface of the N‐terminal Domains of STATs , 2003, Protein science : a publication of the Protein Society.

[83]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[84]  W. Leonard,et al.  IL-2 negatively regulates IL-7 receptor α chain expression in activated T lymphocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[86]  W. Gerald,et al.  Induction of the interleukin-2/15 receptor β-chain by the EWS–WT1 translocation product , 2002, Oncogene.

[87]  W. Leonard.  Cytokines and immunodeficiency diseases , 2001, Nature Reviews Immunology.

[88]  Maria Persico,et al.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis , 2001, Nature Immunology.

[89]  C. Kinnon,et al.  Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. , 2001, Blood.

[90]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[91]  W. Leonard,et al.  The role of Stat5a and Stat5b in signaling by IL-2 family cytokines , 2000, Oncogene.

[92]  H. Niida,et al.  The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. , 2000, Genes & development.

[93]  W. Leonard,et al.  Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity , 1998, The Journal of experimental medicine.

[94]  Steven F. Ziegler,et al.  Defective IL7R expression in T-B+NK + severe combined immunodeficiency , 1998, Nature Genetics.

[95]  E. Serfling,et al.  The Interleukin 2 Receptor α Chain/CD25 Promoter Is a Target for Nuclear Factor of Activated T Cells , 1998, The Journal of experimental medicine.

[96]  Chyung-Ru Wang,et al.  Helper T cell differentiation is controlled by the cell cycle. , 1998, Immunity.

[97]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[98]  C. Roifman,et al.  An interleukin-2 receptor gamma chain mutation with normal thymus morphology. , 1997, The Journal of clinical investigation.

[99]  W. Leonard,et al.  An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. , 1997, Immunity.

[100]  W. Leonard,et al.  The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through noncanonical Egr and Sp1 binding sites , 1997, Molecular and cellular biology.

[101]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[102]  B. Rollins,et al.  Human fibroblasts express functional IL-2 receptors formed by the IL-2R alpha- and beta-chain subunits: association of IL-2 binding with secretion of the monocyte chemoattractant protein-1. , 1996, Journal of immunology.

[103]  W. Leonard,et al.  Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[104]  J. Orange,et al.  Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. , 1995, Journal of immunology.

[105]  W. Leonard,et al.  Role of the Common Cytokine Receptor γ Chain in Cytokine Signaling and Lymphoid Development , 1995, Immunological reviews.

[106]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[107]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.

[108]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[109]  E Morelon,et al.  Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains , 1995, The Journal of cell biology.

[110]  J. Gribben,et al.  Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. , 1994, Science.

[111]  J. Johnston,et al.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.

[112]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[113]  R. Kühn,et al.  IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. , 1994, Journal of immunology.

[114]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, EMBO Journal.

[115]  M. Erdos,et al.  Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling , 1994, Nature.

[116]  B. Nelson,et al.  Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation , 1994, Nature.

[117]  D. Longo,et al.  Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor gamma chain gene expression in human monocytes. , 1994, Blood.

[118]  S. Ziegler,et al.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. , 1993, Science.

[119]  N. Bhat,et al.  Characterization of the human interleukin-2 receptor beta-chain gene promoter: regulation of promoter activity by ets gene products , 1993, Molecular and cellular biology.

[120]  W. Leonard,et al.  Characterization of cDNAs encoding the murine interleukin 2 receptor (IL-2R) gamma chain: chromosomal mapping and tissue specificity of IL-2R gamma chain expression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[121]  A. Zlotnik,et al.  A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. , 1993, Journal of immunology.

[122]  W. Leonard,et al.  Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans , 1993, Cell.

[123]  M. Tsudo,et al.  Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling , 1992, The Journal of experimental medicine.

[124]  N. Tanaka,et al.  Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.

[125]  T. Williams,et al.  Identification of a zinc finger protein that inhibits IL-2 gene expression. , 1991, Science.

[126]  G. Crabtree,et al.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A , 1991, Nature.

[127]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[128]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[129]  J. Abrams,et al.  Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. , 1988, Journal of immunology.

[130]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[131]  Kendall A. Smith,et al.  The interleukin 2 receptor. Functional consequences of its bimolecular structure , 1987, The Journal of experimental medicine.

[132]  J. Lowenthal,et al.  Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor , 1987, The Journal of experimental medicine.

[133]  K. Kato,et al.  Interleukin 2 high-affinity receptor expression requires two distinct binding proteins , 1987, The Journal of experimental medicine.

[134]  T. Waldmann,et al.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[135]  B. Cullen,et al.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. , 1986, Science.

[136]  W. Leonard,et al.  Interleukin 2 receptor gene expression in normal human T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[137]  T. Waldmann,et al.  Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[138]  T. Waldmann,et al.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells , 1984, Nature.

[139]  R. E. Cunningham,et al.  Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. , 1984, Journal of immunology.

[140]  T. Honjo,et al.  Molecular cloning of cDNA encoding human interleukin-2 receptor , 1984, Nature.

[141]  G. Crabtree,et al.  Molecular cloning and expression of cDNAs for the human interleukin-2 receptor , 1984, Nature.

[142]  W. Blattner,et al.  Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. , 1984, The Journal of clinical investigation.

[143]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[144]  T. Waldmann,et al.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor , 1982, Nature.

[145]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[146]  T. Waldmann,et al.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. , 1981, Journal of immunology.

[147]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[148]  Roland Martin,et al.  Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. , 2012, Clinical immunology.

[149]  M. Arkin,et al.  Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. , 2011, Current topics in microbiology and immunology.

[150]  A. Fischer,et al.  Gene therapy for severe combined immunodeficiency. , 2005, Annual review of medicine.

[151]  Jianfei Yang,et al.  T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells , 2002, Nature Immunology.

[152]  L. Glimcher,et al.  NFATc1 and NFATc2 together control both T and B cell activation and differentiation. , 2001, Immunity.

[153]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[154]  W. Leonard,et al.  The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. , 1996, Annual review of medicine.